Isw

In Re Application Of: Cox et al. Serial No. Filing Date Examiner Group Art Unit 3763 THE CHANISM FOR THE DEPLOYMENT OF ENDOVASCULAR IMPLANTS Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 37 CFR 1.97(b) The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: the statement specified in 37 CFR 1.97(e); OR	TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) Docket No. 612-05-CIP2									
10/774,299 February 6, 2004 3763 Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 37 CFR 1.97(b) 1. Image: The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filling of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: the statement specified in 37 CFR 1.97(e); OR	In Re Application Of: Cox et al.									
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 37 CFR 1.97(b) 1. The Information Disclosure Statement submitted herewith is being filed within three months of the filling of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filling of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: The statement specified in 37 CFR 1.97(e); OR										
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 37 CFR 1.97(b) 1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: the statement specified in 37 CFR 1.97(e);	THE MECHANISM FOR THE DEPLOYMENT OF ENDOVASCULAR IMPLANTS									
 The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: the statement specified in 37 CFR 1.97(e); 	Fra TRADEMARY	Commiss P.O	ioner for Patents b. Box 1450	,						
 The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: □ the statement specified in 37 CFR 1.97(e); 	of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office									
OR	CFR 1.97(b), pr Final Action un	Disclosure Statement submitted rovided that the Information Disc der 37 CFR 1.113, a Notice of	I herewith is being filed after closure Statement is filed bef f Allowance under 37 CFR	ore the mailing date of a 1.311, or an Action that						
	☐ the stater	ment specified in 37 CFR 1.97(e)	į							
	☐ the fee se									

TRANSMITTAL O	Docket No. 612-05-CIP2			
In Re Application: (Cox et al.			
Serial No.	Filing Date	Examiner		Group Art Unit
10/774,299	February 6, 2004			3763
MECHANISM FO	OR THE DEPLOYMENT OF EN	DOVASCULAR IMPLANTS		
	•	ment of Fee ects to pay the fee set forth in 37 (CFR 1.1	7(p))
as described belo Charge to Credit an Charge a Certificate of	ereby authorized to charge and cow. ne amount of y overpayment. ny additional fee required. Transmission by Facsimile* ent and authorization to charge deposit mile transmitted to the United States	Certificate of Maili I certify that this docume on HAY/7 254 as first class mail und addressed to the Commis 1450, Alexandria, VA 223	nt and for with the der 37 ssioner 313-145	First Class Mail ee is being deposited e U.S. Postal Service C.F.R. 1.8 and is for Patents, P.O. Box
Trade Disad	Now A Branco Sirving Contists	Carrie Anne Cheung	- C D	Mailine Continue
*This certificate prodeposit account. Howard J. Klein (Reg. No	Name of Person Signing Certificate Try only be used if paying by Signature 1: 28,727) LP (Customer No.: 22145)	Dated: MAY 17, o		

£

र स्ट्रा स्थापित स्थाप <u>स्थाप आर</u>

SIPE	N		612-05-CIP2		10/	774,299			
O, INE	RMATION DISCLOSURE (Use several sheets if neces		Cox et al.						
MAY 2 0 2004	MOE		FILING February 6, 200		GROUP	3763			
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL	DOCUMENT NUMBER	NAME	CLASS	SUBCLASS	FILING DATE				
	4,551,132	11-05-1985	Pasztor et al						
	4,795,741	01-03-1989	Leshchiner et al.						
	4,819,637	04-11-1989	Dormandy, Jr. et al.						
	4,994,069	02-19-1991	Ritchart et al.						
	5,001,009	03-19-1991	Whitbourne						
	5,108,407	04-28-1992	Giremia et al.						
	5,133,731	07-28-1992	Butler et al.						
	5,167,624	12-01-1992	Butler et al.						
	5,226,911	07-13-1993	Chee et al.						
	5,312,415	05-17-1994	Palermo						
	5,331,027	07-19-1994	Whitbourne			·			
		FORE	EIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL YES	LATION NO		
	WO 99/06097	02-11-1999	PCT						
	EP 0 941 703 09-15-199		Europe						
	EP 0 941 704	09-15-1999	Europe						
	WO 00/21443	04-20-2000	PCT						
	EP 1 010 396	06-21-2000	Europe						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
		5	sisted endovascular" Cardiovascu	la consta					
	ROSENTHAL, D. et al	.; "Endovascular	infrainguinal in situ" Journal pof	Vascular Su	rgery; pp. 453	-458			
EXAMINER			DATE CONSIDERED						
	nitial if reference considered, wheth		s in conformance with MPEP 609; Draw I	line through c	itation if not in c	onformance	and not		

Form PTO-A820 (also form PTO-1449)

10/774,299 612-05-CIP2 FORMATION DISCLOSURE CITATION 2 0 2004 (Use several sheets if necessary) Cox et al. FILING GROUP February 6, 2004 3763 TRADEMP **U.S. PATENT DOCUMENTS** FILING DATE EXAMINER NAME CLASS SUBCLASS DOCUMENT NUMBER DATE IF APPROPRIATE INITIAL 09-27-1994 Palermo et al. 5,350,397 5,382,259 01-17-1995 Phelps et al. 01-17-1995 Dormandy, Jr. et al. 5,382,260 12-19-1995 Dormandy, Jr. et al. 5,476,472 5,525,334 06-11-1996 Ito et al. 11-26-1996 5,578,074 Mirigian 12-03-1996 Greff et al. 5,580,568 12-10-1996 Ken 5,582,619 03-11-1997 Benett et al. 5,609,608 04-29-1997 Mariant 5,624,461 07-08-1997 5,645,558 Horton **FOREIGN PATENT DOCUMENTS** TRANSLATION DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) **EXAMINER DATE CONSIDERED** *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ATTY DOCKET NO.

Form PTO-A820 (also form PTO-1449)

SERIAL NO.

(95)					ATTY DOCKET NO. 612-05-CIP2		SERIAL NO. 10/774,299			
•	31	MATION DISCLOSURE (Use several sheets if necess	CITATION eary)		Cox et al.					
MAY 2 0 7	MAY 2 0 2004 E				FILING February 6, 20		GROUP 3763			
Or .	SET S		U.S	. PATENT	DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
1111012	5	,658,308	08-19-1997	Snyder						
	5	,718,711	02-17-1998	Berenst	ein et al.	-				
	5	,750,585	05-12-1998	Park et	al.				•	
	5	,814,062	09-29-1998	Sepetka	et al.					
	5	,823,198	10-20-1998	Jones et	t al.					
	5,891,130 04-06-1999 Pa				o et al.	-4				
	5	5,911,737 06-15-1999			1.					
					Rosenbluth et al. Larson et al.					
	6	6,056,759 05-02-2000			Fiedler					
	6	,063,100	05-16-2000	Diaz et	al.				· -· -, ·	
			. FORE	IGN PATE	NT DOCUMENTS					
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSI YES	ATION NO	
					·					
		OTHER DOCUME	NTS (Includin	g Authoi	r, Title, Date, Pertinent	Pages, Etc	.)			
									**	
EXAMINER					DATE CONSIDERED					
		f reference considered, whethe copy of this form with next co			nance with MPEP 609; Draw	line through o	citation if not in c	onformance	and not	

Form PTO-A820 (also form PTO-1449)

Copyright 1994-97 LegalStar

P09C/REV03

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

ATTY DOCKET NO. SERIAL NO. 612-05-CIP2 10/774,299										
PNEORMATION DISCLOSURE CITATION										
ELLING GROUP										
MAY 2 0 2004 55						February 6, 200	14		3763	
PAR	U.S. PATENT DOCUMENTS *EXAMOUR RADE NAME CLASS SUBCLASS FILING DATE									
EXAMPLER)	RADE		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE	
		6,06	8,644 05-30-2000 Lulo et al.							
	-	6,08	3,220	07-04-2000	Guglielı	mi et al.				
		6,10	2,932	08-15-2000	Kurz					
		6,11	7,142	09-12-2000	Goodso	n et al.				
	6,319,267 11-20-2001 Kurz									·
	6,361,547 03-26-2002 Hieshima									
	6,440,098 08-27-2002 Luscher									
	6,494,884 12-17-2002 Gifford, III et al.									
	6,514,264 02-04-2003 Naglreiter									
		6,54	6,544,225 04-08-2003 Lulo et a			al.				
	6,554,849 04-29-2003 Jones et al.									
FOREIGN PATENT DOCUMENTS										
			DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSI YES	ATION NO
										•
								,		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)										
					<u> </u>		· ··			
EXAMINE	₹					DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

Form PTO-A820 (also form PTO-1449) Copyright 1994 LegalStar

P09C/REV03

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE